The Great National Cancer Vaccine Summit: One Year On

Clinical Diagnostics and Medical Sciences

08:30 am
29 Apr, 2025
15Hatfields Conference Centre, London SE1 8DJ

The Great National Cancer Vaccine Summit: One Year On

Clinical Diagnostics and Medical Sciences

08:30 am
29 Apr, 2025
15Hatfields Conference Centre, London SE1 8DJ

Current Landscape and Challenges:

The UK is leading the way in a groundbreaking National Cancer Vaccine Advance, aiming to transform cancer treatment outcomes by placing 10,000 patients in clinical trials by 2030

Leveraging mRNA technology, originally developed for coronavirus vaccines, this initiative seeks to revolutionise cancer care by seeing advances across multiple cancer types and stages. However, the journey is fraught with challenges, including the personalization of cancer vaccines for individual patients, ensuring timely access to new clinical trials, and integrating innovative treatments seamlessly into existing cancer care pathways.

Timeliness and Importance:

This second event in the series comes at a crucial time, providing a pivotal update for the cancer vaccine and diagnostics community. The progress made over the past year has positioned the UK as a leader in global cancer vaccine research, with the potential to reshape cancer care worldwide.

The advancements in this field not only promise enhanced quality of life for cancer patients but also introduce a new, safer model of cancer care, facilitating quicker, more personalised, and comfortable treatment options.

Key Content Streams:

  1. Personalisation of Cancer Vaccines:

Tailoring treatments to individual patient needs.

Advances in genetic profiling and patient-specific mRNA vaccines.

  1. Access and Speed of Clinical Trials:

Streamlining processes to expedite trial initiation and patient enrolment.

Overcoming regulatory and logistical hurdles.

  1. Integration of New Methodologies:

Incorporating novel treatments into existing cancer care protocols.

Training healthcare professionals in cutting-edge immunotherapy techniques.

  1. Global Implications and Collaborations:

Exploring international partnerships to enhance cancer vaccine research.

Sharing best practices and innovative approaches on a global scale.

The international competition to be the country that delivers 10,000 patients through cancer vaccine trials.

Why Attend:

Join us to be at the forefront of groundbreaking advancements in cancer immunotherapy. This summit offers a unique opportunity to network with leading oncology specialists, researchers, and industry professionals. Attendees will gain valuable insights into the latest research, clinical trials, and technological advancements in cancer vaccines.

The event also provides a platform to foster partnerships that can drive innovation and accelerate the development of cancer vaccines. By participating, you will contribute to shaping the future of cancer care on a global scale, ensuring better outcomes for patients worldwide.

Registration is free for all NHS oncology specialists, NHS staff, and public sector senior leaders and teams. Secure your place today and be a part of this momentous event set to redefine cancer treatment.

Who will Attend

  • Medical oncologists
  • Clinical oncologist
  • Cancer surgeons
  • Cancer trialists
  • Cancer vaccine researchers
  • Cancer trials Unit
  • Cancer alliances
  • NHS Hospital leaderships
  • Public sector research leadership
  • Government Officials

The programme

08:30

Registration and Breakfast

Registration - Open from 9:00 am - Closes at 11:00 am

All delegates must complete their registration process before the 11:00 AM cut-off time. Please arrive in a timely manner to allow for registration and to avoid any inconvenience. Delegates who arrive after the registration deadline will be refused entry to the event.

We appreciate your cooperation in helping us maintain the event's schedule and ensuring that everyone can fully participate in the Cancer Vaccine Conference. If you have any questions or require assistance, our event staff will be available to assist you with the registration process.

Thank you for your understanding, and we look forward to an insightful and productive event together!

09:30

Chair Opening Address: Lennard Lee, University of Oxford associate professor, Senior national clinical advisor for the Office for Life Sciences (Invited)

Chair Opening Address: Lennard Lee, University of Oxford associate professor, Senior national clinical advisor for the Office for Life Sciences (Invited)

09:40

Keynote presentation: Dame Kate Bingham (Invited)

Half a decade on- what is the legacy?

Introduction:

Led by Dame Kate Bingham, this session will evaluate the impact of the National Cancer Vaccine five years post-launch. Dame Kate, renowned for her leadership in vaccine development and biotech investment, will offer her expert insights.

The session will cover the vaccine's development, including its inception, rollout, and initial challenges. It will examine changes in cancer incidence and mortality, along with success stories and patient outcomes.

Further discussion will highlight advances in vaccine technology and treatment protocols, as well as key research collaborations. The influence of the vaccine on healthcare policies, funding, and the economic impact on healthcare and biotech sectors will be analysed.

Looking ahead, the session will explore ongoing research and potential expansions of the vaccine. An interactive Q&A segment will allow attendees to engage with Dame Kate Bingham, discussing the vaccine's future and addressing their questions.

10:00

Panel Discussion: The National Cancer Vaccine Advances: Navigating Challenges and Driving Innovation

  • Prof Christian Ottensmeier, Director of Clinical Research, The Clatterbridge Cancer Centre, Professor of Immuno-Oncology, University of Liverpool
  • Fiona Thistlethwaite, Medical Oncology Consultant, Honorary Senior Lecturer at The University of Manchester “The role of specialist cancer trials centres, in rapidly accelerating technologies like cancer vaccines”.
  • Dr David J. Pinato, Clinician Scientist and Consultant Medical Oncologist, Department of Surgery and Cancer at Imperial College, London. “Placing medicines in mRNA- is this the future for vaccine technology”

10:30

Main Sponsor

Main Sponsor

10:50

Morning Break

Morning Break

11:50

Chair Morning Reflection: Lennard Lee, University of Oxford associate professor, Senior national clinical advisor for the Office for Life Sciences (Invited)

Chair Morning Reflection: Lennard Lee, University of Oxford associate professor, Senior national clinical advisor for the Office for Life Sciences (Invited)

12:00

Case Study

Case Study

12:20

Case Study

Case Study

12:40

Interview session: Professor Sarah Danson, NIHR CRN National Specialty Lead for Early Phase Cancer Research, Chair, the Early Phase Leads Group (Invited)

Introduction:

In this interview, we speak with Professor Sarah Danson, NIHR CRN National Specialty Lead for Early Phase Cancer Research, about the groundbreaking personalised mRNA immunotherapy for melanoma currently undergoing a Phase 3 global clinical trial at University College London Hospital (UCLH). This innovative approach, supported by NIHR infrastructure and developed in collaboration with Moderna and MSD, marks a significant advancement in cancer treatment.

Key Discussion Points:

Sarah Danson will discuss the mechanism behind the treatment, which tailors immunotherapy to each patient's genetic profile to enhance the immune system's ability to target and eliminate cancer cells. She will elaborate on the promising results observed in Phase 2, highlighting a 49% reduction in recurrence or death risk compared to standard treatments, as published in The Lancet.

The interview will explore the pivotal role of the UK Vaccine Innovation Pathway (VIP) and NIHR infrastructure in facilitating this complex clinical trial, ensuring efficient setup and patient recruitment across multiple sites, including geographically remote areas of England.

Sarah will also share insights into eligibility criteria for the Phase 3 trial, aimed at patients who have had high-risk melanomas surgically removed (stage IIB to IV), and the trial's design as a randomised, double-blind study comparing mRNA-4157 and Keytruda versus standard treatment.

The session will conclude with a discussion on the broader implications of this research for cancer treatment and the future directions of personalised medicine in oncology, underscoring the UK's leadership in clinical trials and cancer research.

13:00

Case Study

Case Study

13:20

Lunch and Networking

Lunch and Networking

14:20

Chair Afternoon Address: Lennard Lee, University of Oxford associate professor, Senior national clinical advisor for the Office for Life Sciences (Invited)

Chair Afternoon Address: Lennard Lee, University of Oxford associate professor, Senior national clinical advisor for the Office for Life Sciences (Invited)

14:40

Case Study

Case Study

15:00

Keynote Presentation TBC

Keynote Presentation TBC

15:20

Case Study

Case Study

15:40

Plenary Fireside conversations

  • Professor Thomas Powles, Professor of Genitourinary Oncology; Director, Barts Cancer Centre at St. Bartholomew's Hospital; Lead for Solid Tumour Research. “Aligning the needs of patients with the needs of cancer vaccine technology providers- the potential of speed”
  • Dr Kai-Keen Shiu, consultant in the Gastrointestinal Oncology, Principal Investigator of the UCL/UCLH Gastrointestinal Cancer Translational Research Biobank. “Hereditary and sporadic cancers- advances in GI cancer vaccines”
  • Mr Balaji Venugopal, Consultant Oncologist. “The four nation approach in advancing cancer vaccines- the Scottish innovative ways of working”,
  • Dr. Heather Shaw, Consultant Medical Oncologist, UCL

The cancer vaccine sniffer dogs, how well is it going for melanoma trials”

16:00

Hot Buffet food and drinks

Hot Buffet food and drinks

17:00

End of Day

End of Day

Convenzisvents

Your Pass Includes....

  • Access to a leading conference speaker programme
  • Interactive Q&A sessions
  • Fireside interviews
  • Cross-sector best practice
  • Meet the supplier opportunities
  • Hot breakfast & Lunch included
  • Access to post event drinks reception and Street food

Tickets For NHS Senior Managers

We have an invite only option for NHS Senior Managers for our conference, to see if you qualify for a complimentary place please click the button below.

Register your place

Book tickets

Ticket
Price
Quantity
Charity, Not for Profit and University (In-Person)
£203.99 excl VAT
Limited places
0
Private Sector (In-Person)
£500.00 excl VAT
Limited places
0
Free NHS Ticket
£0.00 No VAT
Limited places
0

Our accreditations

abpco 2021
Manchester Bee
CPD Member
Living Wage Member
Good Employment - Sponsor
Good Employment - Member
Armed Forces Covenant
Tech UK
IHSCM
FSB
Ban The Box
Stockport County
cpdgroup